FXR Agonists Intestinal Selectivity Systemic Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for metabolic disorders, liver diseases, and gastrointestinal conditions associated with farnesoid X receptor (FXR) activity lack effective compounds that can specifically target and modulate FXR activity to address these conditions.
Innovation Solution
Development of novel compounds with specific structures, such as those described in Formula (I), which act as FXR agonists, allowing for targeted modulation of FXR activity to treat metabolic disorders, liver diseases, and gastrointestinal conditions by administering them to the gastrointestinal tract to activate FXR receptors locally, thereby enhancing FXR target gene expression in the intestines while minimizing systemic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic FXR agonists are administered to treat metabolic disorders and liver diseases, then therapeutic efficacy is improved, but systemic side effects increase
Solution Approach 1:
The patent applies local quality by designing compounds with modified physicochemical properties (increased molecular weight, adjusted logP, reduced basicity) that enable selective accumulation in the intestine. This creates a local high concentration of FXR agonist activity in the gastrointestinal tract while maintaining lower systemic concentrations, thereby treating intestinal conditions effectively while minimizing systemic side effects.
Solution Approach 2:
The patent uses intestinal FXR activation as an intermediary mechanism to treat systemic metabolic conditions. By selectively activating FXR in the intestine, the compounds trigger local physiological responses (bile acid secretion, gut hormone release) that subsequently affect systemic metabolism, providing indirect treatment of metabolic disorders with reduced direct systemic exposure.
2Reliability
If FXR agonist compounds are administered to activate FXR receptors, then FXR target gene expression is enhanced, but off-target effects may occur
Solution Approach 1:
The patent systematically modifies key molecular parameters of FXR agonist compounds: increasing molecular weight (300-600 Da), adjusting logP (1-4), reducing basicity (pKa 4-9), and modifying hydrogen bond donor/acceptor counts. These parameter changes collectively enhance intestinal selectivity and reduce off-target binding to other nuclear receptors and enzymes, thereby improving therapeutic specificity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively treat and prevent metabolic disorders, liver diseases, and gastrointestinal conditions by activating FXR receptors in the intestines, reducing systemic side effects and improving insulin sensitivity, lipid metabolism, and energy expenditure, while also addressing conditions like non-alcoholic steatohepatitis, primary biliary cirrhosis, and inflammatory bowel disease.
Implementation Method 1
FXR is a nuclear receptor highly expressed in the liver, intestine, kidney, adrenal glands, and adipose tissue. FXR agonism is a treatment modality for many metabolic disorders, liver diseases or conditions, inflammatory conditions, gastrointestinal diseases, or cell proliferation diseases.
Data Source
AI summary
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.